{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T01:52:12Z","timestamp":1792288332740,"version":"4.4.0"},"reference-count":70,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite the introduction of direct oral anticoagulants (DOACs), the search for more effective and safer antithrombotic strategies continues. Better understanding of the pathogenesis of thrombosis has fostered 2 new approaches to achieving this goal. First, evidence that thrombin may be as important as platelets to thrombosis at sites of arterial injury and that platelets contribute to venous thrombosis has prompted trials comparing anticoagulants with aspirin for secondary prevention in arterial thrombosis and aspirin with anticoagulants for primary and secondary prevention of venous thrombosis. These studies will help identify novel treatment strategies. Second, emerging data that naturally occurring polyphosphates activate the contact system and that this system is critical for thrombus stabilization and growth have identified factor XII (FXII) and FXI as targets for new anticoagulants that may be even safer than the DOACs. Studies are needed to determine whether FXI or FXII is the better target and to compare the efficacy and safety of these new strategies with current standards of care for the prevention or treatment of thrombosis. Focusing on these advances, this article outlines how treatment strategies for thrombosis are evolving and describes the rationale and approaches to targeting FXII and FXI. These emerging anticoagulant strategies should address unmet needs and reduce the systemic underuse of anticoagulation because of the fear of bleeding.<\/jats:p>","DOI":"10.1182\/blood-2016-09-692996","type":"journal-article","created":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T00:10:04Z","timestamp":1477440604000},"page":"147-154","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":78,"title":["Emerging anticoagulant strategies"],"prefix":"10.1182","volume":"129","author":[{"given":"James C.","family":"Fredenburgh","sequence":"first","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, ON, Canada;"},{"name":"Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Gross","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, ON, Canada;"},{"name":"Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, ON, Canada;"},{"name":"Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada; and"},{"name":"Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2019111906121618300_B1","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis: Epidemiologic aspects","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ Res"},{"issue":"9","key":"2019111906121618300_B2","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1161\/CIRCRESAHA.115.306824","article-title":"Systems analysis of thrombus formation","volume":"118","author":"Diamond","year":"2016","journal-title":"Circ Res"},{"issue":"4","key":"2019111906121618300_B3","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jvs.2014.12.050","article-title":"Role of high shear rate in thrombosis","volume":"61","author":"Casa","year":"2015","journal-title":"J Vasc Surg"},{"issue":"9","key":"2019111906121618300_B4","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1111\/j.1538-7836.2006.02138.x","article-title":"Venous thromboembolism and atherosclerosis: common denominators or different diseases?","volume":"4","author":"Agnelli","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019111906121618300_B5","first-page":"924","article-title":"Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome","volume":"112","author":"Weitz","year":"2014","journal-title":"Thromb Haemost"},{"issue":"3","key":"2019111906121618300_B6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s11239-015-1196-4","article-title":"Aspirin in secondary prevention of recurrent venous thromboembolism","volume":"39","author":"Boonyawat","year":"2015","journal-title":"J Thromb Thrombolysis"},{"issue":"Suppl 2","key":"2019111906121618300_B7","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/S0049-3848(16)30363-2","article-title":"Factor XI and factor XII as targets for new anticoagulants","volume":"141","author":"Weitz","year":"2016","journal-title":"Thromb Res"},{"issue":"4","key":"2019111906121618300_B8","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1084\/jem.20112322","article-title":"Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo","volume":"209","author":"von Br\u00fchl","year":"2012","journal-title":"J Exp Med"},{"issue":"4","key":"2019111906121618300_B9","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1182\/blood-2010-05-287623","article-title":"von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models","volume":"117","author":"Brill","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111906121618300_B10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/jth.13181","article-title":"Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice","volume":"14","author":"Geddings","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019111906121618300_B11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1538-7836.2011.04544.x","article-title":"Neutrophil extracellular traps promote deep vein thrombosis in mice","volume":"10","author":"Brill","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019111906121618300_B12","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/ATVBAHA.115.301927","article-title":"2013 scientific sessions Sol Sherry distinguished lecture in thrombosis: polyphosphate: a novel modulator of hemostasis and thrombosis","volume":"35","author":"Smith","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"21","key":"2019111906121618300_B13","doi-asserted-by":"crossref","first-page":"18322","DOI":"10.1074\/jbc.M201173200","article-title":"A model for the stoichiometric regulation of blood coagulation","volume":"277","author":"Hockin","year":"2002","journal-title":"J Biol Chem"},{"issue":"5022","key":"2019111906121618300_B14","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1126\/science.1652157","article-title":"Factor XI activation in a revised model of blood coagulation","volume":"253","author":"Gailani","year":"1991","journal-title":"Science"},{"issue":"8","key":"2019111906121618300_B15","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood-2002-03-0954","article-title":"Coagulation activation and long-term outcome in acute coronary syndromes","volume":"102","author":"Ardissino","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2019111906121618300_B16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111906121618300_B17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1084\/jem.20050664","article-title":"Defective thrombus formation in mice lacking coagulation factor XII","volume":"202","author":"Renn\u00e9","year":"2005","journal-title":"J Exp Med"},{"issue":"Suppl 1","key":"2019111906121618300_B18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1538-7836.2009.03393.x","article-title":"Factor XI deficiency in animal models","volume":"7","author":"Renn\u00e9","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019111906121618300_B19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/jth.13235","article-title":"Contact system revisited: an interface between inflammation, coagulation, and innate immunity","volume":"14","author":"Long","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019111906121618300_B20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/asheducation-2014.1.60","article-title":"Recent insights into the role of the contact pathway in thrombo-inflammatory disorders","volume":"2014","author":"van Montfoort","year":"2014","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"4","key":"2019111906121618300_B21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1055\/s-0031-1276586","article-title":"The plasma contact system 2.0","volume":"37","author":"Maas","year":"2011","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 1","key":"2019111906121618300_B22","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1111\/jth.12961","article-title":"Medical device-induced thrombosis: what causes it and how can we prevent it?","volume":"13","author":"Jaffer","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019111906121618300_B23","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1182\/blood-2008-07-171066","article-title":"Dual role of collagen in factor XII-dependent thrombus formation","volume":"114","author":"van der Meijden","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111906121618300_B24","first-page":"3208","article-title":"Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation","volume":"118","author":"Maas","year":"2008","journal-title":"J Clin Invest"},{"issue":"15","key":"2019111906121618300_B25","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.1073\/pnas.0608647104","article-title":"Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation","volume":"104","author":"Kannemeier","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"2019111906121618300_B26","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2013-05-499384","article-title":"Putting polyphosphates to the test: evidence against platelet-induced activation of factor XII","volume":"122","author":"Fax\u00e4lv","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2019111906121618300_B27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/asheducation-2014.1.52","article-title":"Future prospects for contact factors as therapeutic targets","volume":"2014","author":"Gailani","year":"2014","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"5","key":"2019111906121618300_B28","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1160\/TH13-05-0379","article-title":"Differentiating haemostasis from thrombosis for therapeutic benefit","volume":"110","author":"McFadyen","year":"2013","journal-title":"Thromb Haemost"},{"issue":"9","key":"2019111906121618300_B29","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1161\/CIRCRESAHA.116.306925","article-title":"Evolving treatments for arterial and venous thrombosis: Role of the direct oral anticoagulants","volume":"118","author":"Chan","year":"2016","journal-title":"Circ Res"},{"issue":"2","key":"2019111906121618300_B30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"2019111906121618300_B31","author":"Kirchhof"},{"issue":"4","key":"2019111906121618300_B32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1474-4422(13)70310-7","article-title":"Embolic strokes of undetermined source: the case for a new clinical construct","volume":"13","author":"Hart","year":"2014","journal-title":"Lancet Neurol"},{"issue":"13","key":"2019111906121618300_B33","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/CIRCULATIONAHA.114.008828","article-title":"Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration","volume":"130","author":"Simes","year":"2014","journal-title":"Circulation"},{"issue":"9921","key":"2019111906121618300_B34","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"2019111906121618300_B35","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40256-016-0161-8","article-title":"Suboptimal use of oral anticoagulants in atrial fibrillation: Has the introduction of direct oral anticoagulants improved prescribing practices?","volume":"16","author":"Alamneh","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"issue":"8","key":"2019111906121618300_B36","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.13005","article-title":"Factor XI and contact activation as targets for antithrombotic therapy","volume":"13","author":"Gailani","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019111906121618300_B37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/asheducation-2014.1.66","article-title":"Epidemiologic and clinical data linking factors XI and XII to thrombosis","volume":"2014","author":"Key","year":"2014","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"19","key":"2019111906121618300_B38","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1182\/blood-2011-05-355248","article-title":"Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding","volume":"118","author":"Revenko","year":"2011","journal-title":"Blood"},{"issue":"13","key":"2019111906121618300_B39","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","article-title":"Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits","volume":"123","author":"Yau","year":"2014","journal-title":"Blood"},{"issue":"19","key":"2019111906121618300_B40","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2010-02-270918","article-title":"A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo","volume":"116","author":"Cheng","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111906121618300_B41","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2013-04-499111","article-title":"Factor XII inhibition reduces thrombus formation in a primate thrombosis model","volume":"123","author":"Matafonov","year":"2014","journal-title":"Blood"},{"issue":"22","key":"2019111906121618300_B42","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111906121618300_B43","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1161\/ATVBAHA.113.301282","article-title":"Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates","volume":"33","author":"Crosby","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"353","key":"2019111906121618300_B44","doi-asserted-by":"crossref","first-page":"353ra112","DOI":"10.1126\/scitranslmed.aaf4331","article-title":"Factor XIa-specific IgG and a reversal agent to probe factor XI function in thrombosis and hemostasis","volume":"8","author":"David","year":"2016","journal-title":"Sci Transl Med"},{"issue":"4","key":"2019111906121618300_B45","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood-2008-06-163675","article-title":"Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI","volume":"113","author":"Tucker","year":"2009","journal-title":"Blood"},{"issue":"222","key":"2019111906121618300_B46","doi-asserted-by":"crossref","first-page":"222ra17","DOI":"10.1126\/scitranslmed.3006804","article-title":"A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk","volume":"6","author":"Larsson","year":"2014","journal-title":"Sci Transl Med"},{"issue":"7","key":"2019111906121618300_B47","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/jth.12302","article-title":"Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer","volume":"11","author":"Woodruff","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2019111906121618300_B48","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.bmcl.2006.02.052","article-title":"Synthesis, SAR exploration, and X-ray crystal structures of factor XIa inhibitors containing an alpha-ketothiazole arginine","volume":"16","author":"Deng","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"2019111906121618300_B49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11239-011-0599-0","article-title":"A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits","volume":"32","author":"Wong","year":"2011","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"2019111906121618300_B50","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1021\/jm401670x","article-title":"Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors","volume":"57","author":"Quan","year":"2014","journal-title":"J Med Chem"},{"issue":"3","key":"2019111906121618300_B51","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1021\/jm301338q","article-title":"Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa","volume":"56","author":"Al-Horani","year":"2013","journal-title":"J Med Chem"},{"issue":"11","key":"2019111906121618300_B52","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1021\/jm500311e","article-title":"Designing allosteric inhibitors of factor XIa. Lessons from the interactions of sulfated pentagalloylglucopyranosides","volume":"57","author":"Al-Horani","year":"2014","journal-title":"J Med Chem"},{"issue":"22","key":"2019111906121618300_B53","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood-2014-05-577932","article-title":"Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis","volume":"124","author":"Travers","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2019111906121618300_B54","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1182\/blood-2015-04-641472","article-title":"FXIa and platelet polyphosphate as therapeutic targets during human blood clotting on collagen\/tissue factor surfaces under flow","volume":"126","author":"Zhu","year":"2015","journal-title":"Blood"},{"issue":"32","key":"2019111906121618300_B55","doi-asserted-by":"crossref","first-page":"12938","DOI":"10.1073\/pnas.1204928109","article-title":"Nucleic acid scavengers inhibit thrombosis without increasing bleeding","volume":"109","author":"Jain","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 1","key":"2019111906121618300_B56","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1538-7836.2009.03395.x","article-title":"Factor XI deficiency in humans","volume":"7","author":"Seligsohn","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2019111906121618300_B57","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"342","author":"Meijers","year":"2000","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111906121618300_B58","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2009-05-219915","article-title":"Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology","volume":"114","author":"Cushman","year":"2009","journal-title":"Blood"},{"issue":"18","key":"2019111906121618300_B59","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1161\/CIRCULATIONAHA.110.943738","article-title":"Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the Risk of Arterial Thrombosis in relation to Oral contraceptives (RATIO) case-control study","volume":"122","author":"Siegerink","year":"2010","journal-title":"Circulation"},{"issue":"13","key":"2019111906121618300_B60","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/blood-2005-12-023697","article-title":"Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII","volume":"108","author":"Doggen","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111906121618300_B61","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1046\/j.1538-7836.2003.00195.x","article-title":"Inherited factor XI deficiency confers no protection against acute myocardial infarction","volume":"1","author":"Salomon","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111906121618300_B62","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2141.1994.tb04937.x","article-title":"John Hageman\u2019s factor and deep-vein thrombosis: Leiden thrombophilia Study","volume":"87","author":"Koster","year":"1994","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111906121618300_B63","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1055\/s-0037-1614368","article-title":"Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency--a study on 73 subjects from 14 Swiss families","volume":"82","author":"Zeerleder","year":"1999","journal-title":"Thromb Haemost"},{"issue":"11","key":"2019111906121618300_B64","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1016\/j.actbio.2012.07.019","article-title":"Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo","volume":"8","author":"Yau","year":"2012","journal-title":"Acta Biomater"},{"issue":"8","key":"2019111906121618300_B65","doi-asserted-by":"crossref","first-page":"e002322","DOI":"10.1161\/JAHA.115.002322","article-title":"Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation","volume":"4","author":"Jaffer","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2019111906121618300_B66","article-title":"ISIS-FIXRx, a novel and specific antisense inhibitor of factor XI, caused significant reduction in FXI antigen and activity and increased aPTT without causing bleeding in healthy volunteers [abstract]","author":"Liu","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111906121618300_B67","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"issue":"23 Suppl 1","key":"2019111906121618300_B68","first-page":"I22","article-title":"Natural history of venous thromboembolism","volume":"107","author":"Kearon","year":"2003","journal-title":"Circulation"},{"issue":"3","key":"2019111906121618300_B69","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis","volume":"12","author":"van der Hulle","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"13","key":"2019111906121618300_B70","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/2\/147\/1400360\/blood692996.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/2\/147\/1400360\/blood692996.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T06:27:03Z","timestamp":1574144823000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/2\/147\/36070\/Emerging-anticoagulant-strategies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,12]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,1,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-09-692996","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,12]]}}}